US 12,116,618 B2
Use of aptamers in proteomics
Clive Gavin Brown, Cambridge (GB); Koen Kas, Schilde (BE); and Sven Agnes Jan Eyckerman, Nazareth (BE)
Assigned to Caris Science, Inc., Irving, TX (US)
Filed by Caris Science, Inc., Irving, TX (US)
Filed on Apr. 5, 2021, as Appl. No. 17/222,772.
Application 17/222,772 is a continuation of application No. 16/406,903, filed on May 8, 2019, granted, now 10,995,360.
Application 16/406,903 is a continuation of application No. 15/669,782, filed on Aug. 4, 2017, granted, now 10,316,349, issued on Jun. 11, 2019.
Application 15/669,782 is a continuation of application No. 14/477,907, filed on Sep. 5, 2014, granted, now 9,758,811, issued on Sep. 12, 2017.
Application 14/477,907 is a continuation of application No. 12/682,537, abandoned, previously published as PCT/GB2008/003447, filed on Oct. 10, 2008.
Claims priority of application No. 07020049 (EP), filed on Oct. 12, 2007.
Prior Publication US 2022/0002780 A1, Jan. 6, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6804 (2018.01); C12N 15/11 (2006.01); C12N 15/115 (2010.01); G01N 33/68 (2006.01)
CPC C12Q 1/6804 (2013.01) [C12N 15/111 (2013.01); C12N 15/115 (2013.01); G01N 33/6818 (2013.01); C12N 2310/16 (2013.01); C12N 2320/11 (2013.01)] 20 Claims
 
1. A method for identifying biomarkers of disease states and/or drug treatments, the method comprising:
(a) combining a biological sample, or a derivative thereof, with a plurality of aptamers and allowing members of the plurality of aptamers to bind to their target molecules in the biological sample;
(b) separating members of the plurality of aptamers that bound target molecules in step a) from members of the plurality of aptamers that did not bind target molecules in step a);
(c) using next generation sequencing techniques to sequence at least part of each of the members of the plurality of aptamers that bound the target molecules in step b) to identify and/or quantify each of the bound aptamers;
(d) determining the identity of the target molecules of the bound aptamers and generating a profile of the target molecules;
(e) comparing the profile of the target molecules with a control profile from a control or baseline sample; and
(f) identifying target molecules whose occurrence or expression levels are altered between the biological sample and the control or baseline sample, thereby identifying biomarkers of disease states and/or drug treatments.